Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial

BACKGROUND: Women with HIV face an increased risk of preterm birth. 17 alpha-hydroxyprogesterone caproate (17P) has been shown in some trials to reduce early delivery among women with a history of spontaneous preterm birth. We investigated whether 17P would reduce this risk among women with HIV. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, Joan T, Vwalika, Bellington, Freeman, Bethany L, Cole, Stephen R, Saha, Pooja T, Mbewe, Felistas M, Phiri, Winifreda M, Peterson, Marc, Muyangwa, Dorothy, Sindano, Ntazana, Mwape, Humphrey, Smithmyer, Megan E, Kasaro, Margaret P, Rouse, Dwight J, Goldenberg, Robert L, Chomba, Elwyn, Stringer, Jeffrey S A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476342/
https://www.ncbi.nlm.nih.gov/pubmed/34509197
http://dx.doi.org/10.1016/S2352-3018(21)00150-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476342/
https://www.ncbi.nlm.nih.gov/pubmed/34509197
http://dx.doi.org/10.1016/S2352-3018(21)00150-8

Ejemplares similares